ClinGen Dosage Sensitivity Curation Page

TBR1

Curation Status: Complete

Gene Information

Location Information

Evidence for Loss Phenotypes

Evidence for loss of function phenotype
PubMed ID Description
24458984 Palumbo et al (2015) identified a de novo deletion by SNP array involving the entire TBR1 gene in an individual with slight dysmorphisms, skeletal alterations, and aggressive-impulsive behavior. Probes over flanking genes were not deviating.
25849321 Li et al (2016) used WES/WGS to identify a de novo frameshift variant in exon 1 of 6 of TBR1 in a patient with autism spectrum disorder and another de novo TBR1 frameshift in exon 6 (at amino acid 532) in a patient with intellectual disability.
23160955 O'Roak et al (2012) sequenced 44 candidate genes in 2,446 probands with autism spectrum disorder. They identified a de novo frameshift in exon 1 of TBR1 in one patient. This patient also had a rare, paternally-inherited duplication of at least 315 kb. Another patient was found to have a de novo frameshift in exon 4. Potentially de novo events were confirmed by Sanger sequencing in this study.

Evidence for Triplosenstive Phenotype

NOTE:The loss of function score should be used to evaluate deletions, and the triplosensitivity score should be used to evaluated duplications. CNVs encompassing more than one gene must be evaluated in their totality (e.g. overall size, gain vs. loss, presence of other genes, etc). The rating of a single gene within the CNV should not necessarily be the only criteria by which one defines a clinical interpretation. Individual interpretations must take into account the phenotype described for the patient as well as issues of penetrance and expressivity of the disorder. ACMG has published guidelines for the characterization of postnatal CNVs, and these recommendations should be utilized (Genet Med (2011)13: 680-685). Exceptions to these interpretive correlations will occur, and clinical judgment should always be exercised.